

L4 ANSWER 4 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 AN 93001761 EMBASE
 DN 1993001761
 TI The treatment of Peyronie's disease with tamoxifen.
 AU Ralph D.J.; Brooks M.D.; Bottazzo G.F.; Pryor J.P.
 CS Institute of Urology, Middlesex Hospital, Mortimer Street, London W1 8HH,
 United Kingdom
 SO British Journal of Urology, (1992) 70/6 (648-651).
 ISSN: 0007-1331 CODEN: BJURAN
 CY United Kingdom
 DT Journal; Article
 FS 028 Urology and Nephrology
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LA • English
 SL English
 AB This is a preliminary study of the treatment of 36 patients with
 Peyronie's disease who received tamoxifen 20 mg twice daily for
 3 months. An improvement occurred in 16 of 20 patients with penile pain,
 in 11 of 31 patients with an erectile deformity and 12 of 35
 patients had a plaque shrinkage of at least 1 cm. Some improvement
 occurred in 6 of the 8 patients with a histologically confirmed
 inflammatory infiltrate of the plaque but not in any of the 4 patients
 without an infiltrate. The inflammatory infiltrate was found in patients
 in whom the duration of the disease was less than 4 months.
 CT Medical Descriptors:
 *pain
 *penis
 *peyronie disease: DT, drug therapy
 adult
 aged
 article
 clinical article
 controlled study
 hot flush: SI, side effect
 human
 libido loss: SI, side effect
 male
 oral drug administration
 priority journal
 t lymphocyte
 Drug Descriptors:
 *tamoxifen: AE, adverse drug reaction
 *tamoxifen: DT, drug therapy
 *tamoxifen: DO, drug dose
 RN (tamoxifen) 10540-29-1